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In the last decade, important advances have been made in understanding of cancer biology, particularly non-small-cell
lung cancer (NSCLC) with the discovery of oncogenic drivers of the disease. The epidermal growth factor receptor
(EGFR) gene and its pathways was the first oncogenic driver discovered to be mutated and treatable in lung cancer.
Treatment with EGFR tyrosine kinase inhibitors (TKIs) is the standard of care for molecularly selected EGFR-mutant
patients, while its role in unselected lung cancer patients is nowadays controversial. This review will provide an
overview of the EGFR pathway and options for its treatment of lung cancer.
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The majority of non-small-cell lung cancer (NSCLC) pa-
tients are diagnosed with locally advanced or metastatic
disease, meaning chemotherapy is the treatment of choice.
However, despite advances, treatment with chemotherapy
offers an overall survival (OS) benefit usually restricted to
only a few months [1-3]. However, the outlook in NSCLC
has changed significantly in the few last years. Lung
cancer comprises a group of diseases with distinct mo-
lecular profiles and sensitivity to different treatments. It is
mandatory therefore to determine and classify NSCLC
molecular subtypes and to develop molecular diagnostics
to identify them.
Our understanding of the role of molecular alterations
in NSCLC has increased in recent years, leading to the
discovery of driver alterations and the development of
targeted therapies which has increased survival for a
small, but significant group of patients. Mutations in the
epidermal growth factor receptor (EGFR) gene and rear-
rangements of the anaplastic lymphoma kinase (ALK)
gene are markers for determining the appropriate treat-
ment for advanced NSCLC [4] and have now passed into
routine clinical use as predictive biomarkers. Other
potential predictive biomarkers such as ROS1, BRAF,* Correspondence: ecarcereny@iconcologia.net
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in any medium, provided the original work is pHER2 or MET have also been identified and efforts are
underway to target them with novel drugs.Review
EGFR biology in lung cancer
The EGFR gene is located on chromosome 7p12–13 and
belongs to a family of cell membrane receptor tyrosine ki-
nases that include EGFR (ERBB1), HER2/c-neu (ERBB2),
HER3 (ERBB3) and HER4 (ERBB4). Among these HER
family members, EGFR and HER2 are the most commonly
altered receptors in cancer. These receptors are single
amino acid chain proteins that possess an extracellular
ligand binding domain, a single hydrophobic transmem-
brane domain that is involved in interaction between re-
ceptors, and an intracellular domain with tyrosine
kinase activity [5].
EGFR activation can be induced through autocrine or
paracrine ligands with different affinities for the ErbB re-
ceptors [6]. There are six major EGFR ligands including:
epidermal growth factor, transforming growth factor alpha,
heparin binding EGF, betacellulin, amphiregulin and
heregulin. In EGFR, ligand binding induces a conform-
ational change that facilitates receptor homo or heterodi-
mer complexes among four receptors, thereby resulting in
activation of EGFR tyrosine kinase activity. This auto-
phosphorylation leads to downstream activation and
signaling by several other proteins through their
own phosphotyrosine-binding SH2 domains, initiatingis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tumor cells, principally the RAS/RAF/MAPK pathway
which plays an important role in regulating cell prolifer-
ation, migration and differentiation, and the PI3K/AKT
pathway which controls cellular survival and antiapop-
totic signals [7] (Figure 1). EGFR signaling pathways
play an important role in the development of malignancy
through modulation of cell cycle progression, inhibition of
apoptosis, induction of angiogenesis and promotion of
tumor cell motility and metastasis [8]. EGFR is known to
be expressed more abundantly in malignant than in nor-
mal tissue, including 40–80% of NSCLC.
Several mechanisms lead to aberrant receptor activation,
including: receptor overexpression, gene amplification, ac-
tivating mutations, overexpression of receptor ligands,
and/or loss of their negative regulatory mechanisms.Targeting EGFR in unselected populations
Interest in developing anti-EGFR treatments for specific
tumors such as colon cancer and NSCLC has led to the
development of two classes of drugs: monoclonal anti-
bodies and TKIs. TKIs are small molecules that compete
with and prevent binding of adenosine triphosphate to
the intracellular tyrosine kinase region. These agents
cause tumor regression by increasing apoptosis and inhi-
biting cellular proliferation and angiogenesis.Figure 1 Epidermal growth factor receptor pathway.First line and maintenance treatment
Two TKIs (gefitinib and erlotinib) and one monoclonal
antibody (cetuximab) have been tested in the first line
setting.
Gefitinib (ZD1839, Iressa®), is an oral EGFR-specific
anilinoquinazoline which reversibly inhibits autophos-
phorylation and a shift of cells from S phase to G0/G1
[9]. Two phase III trials in chemotherapy naïve stage
IIIB/IV NSCLC patients have so far been reported (IN-
TACT 1 and 2). These multinational, randomized,
double blind trials of chemotherapy (gemcitabine plus cis-
platin in INTACT 1; paclitaxel plus carboplatin in IN-
TACT 2) in combination with gefitinib or placebo, failed
to demonstrate any improvement in OS. In INTACT 1
[10], 1093 patients were included and no difference in effi-
cacy was observed between the treatment arms. For treat-
ment with gefitinib 500 mg/d, 250 mg/d and placebo,
median survival was 9.9, 9.9 and 10.9 months, respectively.
In INTACT 2 [11], 1037 patients were included in the
same three arms with no difference in OS (median 8.7,
9.8, and 9.9 months for gefitinib 500 mg/d, 250 mg/d and
placebo, respectively).
Erlotinib (CP-358774, OSI 774, Tarceva®) is another ani-
linoquinazoline derivative, orally active EGFR inhibitor
that can induce both cell-cycle arrest in G1 and apoptosis.
Phase I studies led to the determination of a 150 mg per
day dose due to its safety profile and pharmacokinetic
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combination of erlotinib plus chemotherapy (paclitaxel
and carboplatin in the TRIBUTE trial and gemcitabine
and cisplatin in the TALENT trial). Both trials failed to
show a survival benefit in patients treated with the com-
bination [13,14]. In the TRIBUTE trial, 1059 patients
were included with a median survival of 10.6 months
and 10.5 months for the erlotinib and placebo arms, re-
spectively. In the TALENT trial, 1172 patients were in-
cluded with a median survival of 10.75 and 11 months
for erlotinib and placebo, respectively.
Erlotinib has been also explored in the maintenance
setting after first-line treatment in three randomized tri-
als (SATURN, ATLAS and IFTC-GFPC 0502). The
SATURN study demonstrated superior OS of 12.3
months in the erlotinib group vs 11.1 months in the pla-
cebo group (HR 0.81; 95% CI: 0.70-0.95; p = 0.0088).
Only 21% of patients in the placebo group ever received
erlotinib. OS for the EGFR-mutant patients had not been
reached for this subgroup receiving erlotinib at time of
publication (HR 0.83; 95% CI: 0.34-2.02; p = 0.6810). Pa-
tients who had stable disease after first-line chemother-
apy seemed to have a more pronounced OS benefit
(median 11.9 vs 9.6 months with placebo; HR 0.72; 95%
CI: 0.59-0.89; p = 0.0019) than those who responded
(median 12.5 vs 12.0 months with placebo; HR 0.94; 95%
CI: 0.74-1.20; p = 0.618) [15] Biomarker analysis for
EGFR mutation status showed that erlotinib was active
in patients with EGFR-activating mutations (HR 0.10;
95% CI: 0.04-0.25; p < 0.0001) and in those with wild-
type EGFR (HR 0.78; 95% CI: 0.63-0.96; p = 0.0185). In
the ATLAS trial, 743 patients were randomized (1:1) to
bevacizumab plus either placebo or erlotinib after four
cycles of chemotherapy plus bevacizumab without dis-
ease progression or significant toxicity. The primary end
point was progression free survival (PFS). Median PFS
was 3.7 months with bevacizumab/placebo and 4.8
months with bevacizumab/erlotinib (HR 0.71; 95% CI,
0.58 to 0.86; p < 0.001). There were no differences in OS
[16]. IFTC-GFPC0502 investigated whether continuation
maintenance with gemcitabine or a switch with erlotinib
improves clinical outcome compared with observation in
patients with advanced NSCLC whose disease was con-
trolled after cisplatin-gemcitabine induction chemotherapy.
PFS was significantly prolonged by gemcitabine (median,
3.8 vs 1.9 months; HR 0.56; 95% CI, 0.44 to 0.72; p < 0.001)
and erlotinib (median, 2.9 vs 1.9 months; HR, 0.69; 95% CI,
0.54 to 0.88; p = 0.003) vs observation but neither mainten-
ance strategy resulted in an improvement in OS [17].
Cetuximab (Erbitux®) has also been tested in first line. In
a phase III, multinational, multicenter, open-label trial,
1125 advanced NSCLC patients were randomly assigned
(1:1) to chemotherapy (cisplatin plus vinorelbine for up to
six cycles) plus cetuximab or chemotherapy alone. Theprimary endpoint was OS. Cetuximab was continued until
disease progression or unacceptable toxicity. OS was lon-
ger with cetuximab than chemotherapy alone (median
11.3 months vs 10.1 months; HR 0.871; 95% CI 0.762-
0.996; p = 0.044) with no differences in PFS [18].
Second line and beyond
EGFR TKIs have also been tested following first line
treatment for advanced NSCLC. Two large phase II, ran-
domized trials (IDEAL 1–2) have been reported using
gefitinib. In the IDEAL 1 study [19], 210 NSCLC pa-
tients who had failed one or two chemotherapy regimens
(at least one platinum-based therapy) were randomly
assigned to receive 250 mg or 500 mg per day of gefitinib.
In the IDEAL 2 study [20], 216 patients who had failed
two or more chemotherapy regimens containing platinum
and docetaxel received 250 mg or 500 mg gefitinib per
day. There were no differences between the two doses
with regard to response rate, time to progression or me-
dian survival. An increased incidence of adverse events in
patients receiving 500 mg per day was seen in both trials.
Three phase III trials have been performed in this setting
with gefitinib. ISEL is a randomized, placebo controlled,
phase III trial of gefitinib in chemotherapy-refractory
NSCLC patients. Median survival was 5.6 months in the
gefitinib group and 5.1 months in the placebo group, fail-
ing to demonstrate a benefit [21]. The V-15-32 study en-
rolled 484 Japanese patients in a non-inferiority trial that
compared OS with gefitinib vs docetaxel in NSCLC pa-
tients who had failed one or two chemotherapy regimens.
Non-inferiority in OS was not achieved (HR 1.12; 95% CI,
0.89 to 1.40) [22]. In the INTEREST phase III trial, 1466
patients were enrolled in second line. The results of this
study demonstrated non-inferiority of gefitinib vs doce-
taxel in terms of OS with a median 7.6 and 8.0 months
(HR 1.020, 95% CI 0.905-1.150). Gefitinib was better toler-
ated and quality of life evaluation favored its use [23].
Erlotinib has been evaluated following first line treat-
ment in three trials. The BR.21 trial enrolled advanced
NSCLC patients with performance status 0 to 3 and ran-
domized them to receive erlotinib or placebo in second
or third line. The trial was the first to demonstrate activ-
ity of an EGFR TKI in NSCLC with response rate of
8.9% in the erlotinib group and less than 1% in the pla-
cebo group (p < 0.001). PFS was 2.2 months and 1.8
months, respectively (HR 0.61; p < 0.001). OS was 6.7
months with erlotinib and 4.7 months with placebo (HR
0.70; p < 0.001) [24]. On the basis of these results, erloti-
nib was approved by the FDA in November 2004 and by
the EMEA in October 2005 for second and third line
treatment of NSCLC patients. TAILOR is a randomized
controlled trial in 52 Italian hospitals in advanced EGFR
wild-type NSCLC patients who had received platinum-
based chemotherapy. Seven hundred and two patients
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lotinib or docetaxel. Median OS was 8.2 months (95% CI
5.8-10.9) with docetaxel vs 5.4 months (95% CI 4.5-6.8)
with erlotinib (HR 0.73, 95% CI 0.53-1.00; p=0.05). Me-
dian PFS was 2.9 months (95% CI 2.4-3.8) with docetaxel
vs 2.4 months (95% CI 2.1-2.6) with erlotinib (HR 0.71,
95% CI 0.53-0.95; p = 0.02) [25]. The TITAN trial was a
randomized, open-label, phase III study carried out at 77
sites in 24 countries. Four hundred and twenty four
NSCLC patients with disease progression after chemother-
apy were randomly assigned to receive erlotinib or chemo-
therapy (standard docetaxel or pemetrexed). Median OS
was 5.3 months (95% CI 4.0-6.0) with erlotinib and 5.5
months (95% CI 4.4-7.1) with chemotherapy (HR 0.96,
95% CI 0.78-1.19; p = 0.73) [26].
Targeting EGFR in selected populations: EGFR mutations
Since only 8.9% of unselected NSCLC patients responded
to EGFR TKI [24], several studies have tried to find prog-
nostic and predictive biomarkers of sensitivity or resistance
to anti-EGFR agents. For example: EGFR mutations, EGFR
gene copy numbers, status of EGFR ligands, changes in
other HER family genes or molecules downstream to EGFR
including KRAS or AKT. However, only EGFR mutations
have been demonstrated a strong correlation with efficacy
of EGFR TKIs in different prospective trials.
In 2004, three different groups found that a subset of
NSCLC patients have somatic, activating mutations of
the EGFR gene [27-29]. Following these initial reports,
various groups have confirmed and extended the findings.
Mutations in this gene in lung cancer have been located in
four exons, from 18 to 21, which encode the kinase do-
main [30]. More than 188 EGFR mutations have been re-
ported but just two - deletion of 5 amino acids from exon
19 and the missense mutation in exon 21 resulting in a
substitution of arginine for leucine at position 858 (L858R)
- account for 80-90% [31]. These activating mutations
occur in the ATP binding domain, leading to a constitu-
tively active receptor. Importantly, these changes also lead
to superior binding of the domain to targeted TKI com-
pared with ATP [32,33]. Several less common mutations,
such as G719X, L861X, and insertions at exon 19, have
demonstrated drug sensitivity, whereas others appear less
responsive (such as, EGFR exon 20 insertion mutations).
These molecular alterations are most common in Asian
patients, adenocarcinoma histology, female gender and
never smokers, who are known to be candidates for harbor
EGFR mutations [34,35].
The IPASS was the first phase III trial to analyze the effi-
cacy of an EGFR TKI in EGFR-mutant NSCLC patients,
selected according to clinical characteristics. This open-
label, phase III study randomized 1217 previously un-
treated, advanced NSCLC, non smokers or former light
smoker patients from East Asia with adenocarcinomahistology to receive gefitinib or carboplatin plus paclitaxel.
The study met its primary objective of non inferiority of ge-
fitinib. A total of 683 patients (56.1%) provided samples.
EGFRmutation data for 437 patients (35.9%) was evaluated.
Of the 437 samples, 59.7% were positive for a mutation:
140 (53.6%) had exon 19 deletions; 111 (42.5%) had a muta-
tion at exon 21 (L858R). In the subgroup of 261 mutation
positive patients, PFS was significantly longer among those
who received gefitinib than chemotherapy (HR 0.48; 95%
CI, 0.36 to 0.64; p < 0.001), whereas in the subgroup of 176
patients negative for the mutation, PFS was significantly
longer among those who received carboplatin-paclitaxel
(HR 2.85; 95% CI, 2.05 to 3.98; p < 0.001). A higher object-
ive response rate (RR) (71.2% vs 47.3% with chemotherapy)
was observed among patients who received gefitinib [36].
In addition to the IPASS findings, there have been six
randomized controlled phase III trials comparing EGFR
TKIs (gefitinib, erlotinib or afatinib) to chemotherapy in
EGFR-mutant lung cancer patients, both in Asian and
Caucasian populations (Table 1). These studies uniformly
show superior RRs, PFS and quality of life with EGFR
TKIs compared to chemotherapy. No differences in OS
were shown, except for with afatinib. In the WJTOG3405
phase III trial, 177 chemotherapy-naïve, EGFR mutated
(either exon 19 deletion or L858R point mutation), ad-
vanced NSCLC patients from 36 centers in Japan were
randomly assigned to receive either gefitinib or cisplatin
plus docetaxel for three to six cycles. The gefitinib arm
had significantly longer PFS compared with the cisplatin
plus docetaxel group, 9.2 months (95% CI 8.0-13.9) vs 6.3
months (9% CI 5.8-7.8; HR 0.489, 95% CI 0.336-0.710, p <
0.0001) [37]. The NEJ002 study included 230 patients en-
rolled from 43 centers in Japan. PFS was significantly lon-
ger in the gefitinib group, 10.8 months, vs 5.4 months
with chemotherapy (HR, 0.30; 95% CI, 0.22 to 0.41; p <
0.001). The objective RR was significantly higher in the ge-
fitinib group (73.7% vs. 30.7%, p <0.001). OS did not differ
significantly between the two treatment groups [38].
Two trials, the OPTIMAL and the EURTAC, have been
carried out in this setting with erlotinib. The OPTIMAL
study was an open-label, randomized, phase III trial involv-
ing 22 centers in China. One hundred and sixty five pa-
tients were randomly assigned to receive either erlotinib or
carboplatin plus gemcitabine. Median PFS was 13.1 months
(95% CI 10.58-16.53) in erlotinib-treated patients vs 4.6
months (4.21-5.42) (HR 0.16, 95% CI 0.10-0.26; p < 0.0001).
Overall response rate (ORR) was 83% (68/82) for erlotinib
and 36% for chemotherapy (P < 0.0001) [39]. The EURTAC
trial was an open-label, randomized phase III study con-
ducted in 42 hospitals in Spain, France and Italy and is the
only trial to date in a Caucasian population. EGFR-mutant
NSCLC patients were randomized to erlotinib or standard
chemotherapy with cisplatin or carboplatin plus docetaxel
or gemcitabine. The primary endpoint was PFS. One
Table 1 Phase III trials of EGFR TKIs versus chemotherapy as first line therapy in NSCLC EGFR mutated patients
Study TKI Chemotherapy Population Response rate
(EGFR TKI vs chemotherapy) %
Disease control rate
(EGFR TKI vs chemo) %
Progression free survival
(EGFR TKI vs chemo) m
Overall survival
(EGFR TKI vs chemo) m
IPASS (Sub-study)1 Gefitinib Carbo/Pac Asian (E/SE) 71.2 47.3 91.7 87.6 9 6 21.6 21.9
p 0.001 p 0.001 NS
EURTAC2 Erlotinib Cis OR Carbo +
Doc OR Gem
Caucasian 58 15 79 66 9.4 5.2 NR NR
p < 0.001 p <0.001 p < 0.0001
OPTIMAL3 Erlotinib Carbo/Gem Asian (China) 83 36 96 82 13.1 4.6 NR NR
p 0.00001 p <0.0001 p < 0.0001
WJTOG 34054 Gefitinib Cis/Doc Asian (Japan) 62.1 32.2 93.1 78 9.2 6.3 30.9 NR
p < 0.0001 p 0.02 p < 0.0001 p 0.211
NEJSG 0025 Gefitinib Carbo/Pac Asian (Japan) 73.7 30 86 79 10.8 5.4 30.5 23.6
p < 0.001 p < 0.001 p 0.353
LUX-Lung 36 Afatinib Cis/Pem Majority Asian 56.1 22.6 NR NR 11.1 6.9 31.6 28.2
p < 0.0001 p 0.0004 p 0.109
LUX-Lung 67 Afatinib Cis/Gem Asian (E/SE) 67 23 93 76 11 5.6 23.6 23.5
p < 0.0001 p < 0.0001 p 0.001 p0.175
1Mok, et al. N Engl J Med 2009 [36]; 2; 2Rosell, et al. Lancet Oncol 2012 [40]; 3Zhou, et al. Lancet Oncol 2011 [39]; 4Mitsudomi, et al. Lancet Oncol 2010 [37]; 5Maemondo, et al. N Engl J Med 2010 [38]; 6Sequist, et al.
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screened and 174 with EGFR mutations enrolled. The pre-
planned interim analysis showed that the study met its
primary endpoint: median PFS was 9.7 months (95% CI
8.4-12.3) in the erlotinib group, compared with 5.2
months (95% CI 4.5-5.8) in the chemotherapy group (HR
0.37, 95% CI 0.25-0.54; p < 0 0001) [40].
Afatinib (BIBW 2992, Gilotrif®, Giotrif®,) is an irrevers-
ible, pan-HER inhibitor that blocks all members of the
HER family with tyrosine kinase properties (EGFR, HER2,
and HER4). It is an ATP-competitive aniline-quinazoline
compound with a reactive acrylamide group that irrevers-
ibly binds to cysteine residues within the kinase domain of
EGFR and HER2 [41]. Moreover, afatinib is able to inhibit
kinase activity in vitro and in animal models when a resist-
ant T790M mutation is concomitant to a sensitive muta-
tion. The LUX-Lung 2 was a single arm phase II trial that
assessed activity of two doses of afatinib (40 mg and 50
mg daily) as first- or second-line treatment in 129 NSCLC
patients harboring EGFR mutations. Ninety nine patients
started afatinib at 50 mg and 30 patients at 40 mg. ORR
was 61%, with no significant differences according to the
dose. As no apparent difference in activity was highlighted
between the two groups of patients, 40 mg dosing was
chosen for phase III trials. Median PFS was 10.1 months
and OS 24.8 months for all patients [42]. LUX-Lung 3 and
LUX-Lung 6 were phase III trials in first line with afatinib
vs chemotherapy in this population. LUX-Lung 3 random-
ized (2:1) 345 patients to receive afatinib or a combination
of cisplatin and pemetrexed. This trial included 27% non-
Asians patients and patients with uncommon mutations.
Median PFS was 11.1 months for afatinib compared to 6.9
months for chemotherapy (HR: 0.58; 95% CI: 0.43–0.78;
p = 0.001). Better PFS of 13.6 months was shown in pa-
tients with common activating mutations (exon 19 dele-
tions and exon 21 point mutations) [43]. The LUX-Lung 3
is a phase III trial with a similar design to LUX-Lung 6 in
364 Asian patients. Patients in the control arm received
cisplatin plus gemcitabine. Patients receiving afatinib com-
pared to chemotherapy had significantly prolonged PFSFigure 2 Mechanisms of acquired resistance to EGFR-tyrosine kinase(11 vs 5.6 months, HR 0.28, 95% CI: 0.20–0.39; p = 0.0001)
as well as higher ORR ( 66.9 vs 23%; p = 0.0001) [44]. A
clinical trial comparing afatinib to gefitinib is already on-
going (LUX-Lung 7) but no data are yet available. How-
ever, EGFR TKIs had not demonstrated a benefit in OS
until ASCO 2014. OS results for LUX-Lung 6 and 3 were
presented at the ASCO annual congress 2014. The studies
showed median OS for common mutations of 27.3
months in the afatinib arm vs 24.3 months in the chemo-
therapy arm (HR 0.81; 95% CI 0.66-0.99; p = 0.0374) [45].
Despite impressive results in RR and PFS, clinical failure
is eventually inevitable in these patients. Serial biopsies of
tumors taken before and after EGFR TKI treatment have
provided insight into the mechanisms of treatment failure
[46] (Figure 2). In around 60% of cases, this is mediated by
the presence of the secondary EGFR T790M mutation re-
sistant to inhibition by current EGFR TKIs; however, other
mechanisms have also been described [47,48]. Different
strategies could be applied beyond progression, such as
addition of chemotherapy, switching to chemotherapy or
continuing EGFR TKI.
Recently, third-generation EGFR inhibitors, such as
WZ4002, CO-1686, HM61713 and AZD9291, have been
developed and interesting results from phase I trials
were presented at ASCO 2014 [49,50].
Conclusions
At last, a revolution is taking place in lung cancer treat-
ment. The discovery of driver mutations and their treat-
ment has changed our understanding of cancer. The EGFR
pathway plays an important role in lung cancer, especially
EGFR mutations which have opened up the possibility of a
personalized medicine approach to this disease. EGFR TKIs
are a treatment option in unselected populations after first
line, though this remains controversial. However, EGFR
TKIs are now standard treatment in EGFR-mutant patients,
where phase III trials have demonstrated a clear efficacy
benefit. There still remains much work to do in this setting,
and, with ever-growing knowledge, we are likely to see fun-
damental changes in clinical practice in the coming years.inhibitor.
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